Motion Sickness, Space
3
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Scopolamine
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Virtual Reality in the Rehabilitation of Visually Induced Motion Sickness
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Research Network
Common Treatments
- Scopolamine2
- The Effects Of Virtual Reality Exposure Were Assessed Using Posturography1
- Other Eg Promethazine Meclizine1
Active Sponsors
- Repurposed Therapeutics, Inc.2
- National Aeronautics and Space Administration (NASA)2
- Istanbul Aydın University1
Top Investigators
National Aeronautics and Space Administration (NASA)
Istanbul Aydın University
Related Conditions
- Visually Induced Motion Sickness1
- Sea Sickness1
- Vestibular Rehabilitation In Ms1
- Parabolic Flight1
- Motion Simulation1